Precigen Inc., a biopharmaceutical company, reported its financial results for the first quarter of 2025, highlighting a significant shift in its financial metrics. The company experienced a change in total other income (expense), net, which shifted from an income of $0.6 million in the first quarter of 2024 to an expense of $31.6 million in the same period in 2025. This shift was primarily due to a $32.5 million increase in the fair value of warrant liabilities, influenced by a rise in Precigen's stock price and an increase in the liability related to additional warrants from paid-in-kind dividends of Series A Preferred Stock. This was partially offset by a $0.3 million increase in interest income due to higher investment balances. Precigen reported a net loss of $54.2 million, compared to a net loss of $23.7 million in the first quarter of 2024. The non-cash change in the fair value of warrant liabilities decreased the basic and diluted earnings per share by $0.11 in the first quarter of 2025. Additionally, the company ended the quarter with $81 million in cash, cash equivalents, and investments. Precigen's CFO, Harry Thomasian Jr., stated that this cash position is expected to fund operations into 2026, even considering a potential commercial launch of PRGN-2012 later in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.